Elisa Sensi

FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study

Chiara Cremolini, Fotios Loupakis, Carlotta Antoniotti et al. · The Lancet Oncology · 2015 · 1.1K citations · Full text

Phase 3, Gastrointestinal Oncology, Medicine +8

Prophylactic Central Compartment Lymph Node Dissection in Papillary Thyroid Carcinoma: Clinical Implications Derived From the First Prospective Randomized Controlled Single Institution Study

David Viola, Gabriele Materazzi, Laura Valerio et al. · The Journal of Clinical Endocrinology & Metabolism · 2015 · 317 citations · Full text

Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial

Gianluca Masi, Fotios Loupakis, Lisa Salvatore et al. · The Lancet Oncology · 2010 · 240 citations

Oncology, Gastrointestinal Oncology, Medicine +9

FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer

Fotios Loupakis, Chiara Cremolini, Lisa Salvatore et al. · European Journal of Cancer · 2013 · 185 citations

Gastrointestinal Oncology, Medicine, Pharmacology +7

Correlation between the <i>BRAF</i> V600E Mutation and Tumor Invasiveness in Papillary Thyroid Carcinomas Smaller than 20 Millimeters: Analysis of 1060 Cases

Fulvio Basolo, Liborio Torregrossa, Riccardo Giannini et al. · The Journal of Clinical Endocrinology & Metabolism · 2010 · 184 citations · Full text